Acquires of Minaris Regenerative Medicine by Altaris, a US healthcare fund (represented Altaris) Home Practices Acquires of Minaris Regenerative Medicine by Altaris, a US healthcare fund (represented Altaris) Period September, 2024 Practices M&A People Kenichi Sekiguchi Kenichi Sekiguchi Partner Tokyo +81-3-6266-8562 kenichi.sekiguchi@morihamada.com M&A Corporate Law Asset Management / Funds Dispute Resolution Yasutaka Tokuda Yasutaka Tokuda Partner Tokyo +81-3-6266-8934 yasutaka.tokuda@morihamada.com M&A Crisis Management / Compliance Life Science / Healthcare Consumer Law Public Policy Masaaki Hirota Masaaki Hirota Partner Tokyo +81-3-6266-8985 masaaki.hirota@morihamada.com M&A Structured Finance / Banking Fumiya Sunose Fumiya Sunose Senior Associate Tokyo +81-3-5223-7791 M&A Corporate Law Yurika Inoue Yurika Inoue Senior Associate Tokyo +81-3-6213-8163 M&A Life Science / Healthcare Intellectual Property Corporate Law Capital Markets Related Cases May, 2025 Case Highlights NTT: Acquisition of NTT Data for JPY 2.37 trillion Minoru Sawaguchi Akira Matsushita Shimpei Ochi April, 2025 Privatization of AEON MALL Katsumasa Suzuki Takafumi Goto April, 2025 Mori Hamada advised gumi in its formation of blockchain node operating JV in Japan with TIS Masafumi Masuda Takaaki Okano Kosuke Esumi April, 2025 Represented TENMA CORPORATION in connection with MBO by FHL Holdings Inc. through a tender offer Yohei Koyama Kohei Morita Yurika Inoue Yasuhisa Watanabe Taishu Yamashita Taishi Koyama March, 2025 Case Highlights T&D Holdings: Acquisition of Viridium Group from Cinven Limited Kenichi Sekiguchi Kazuo Yoshida Makoto Sakai Henry Lau Hiromu Suemasa Jaejoong Kim Hiroki Inomata March, 2025 Case Highlights Investment in class shares of Toho Zinc by funds serviced by Advantage Partners Masakazu Kumagai Tetsuya Tamura Tomohiro Oka Go back to Cases